COMPARATIVE ANALYSIS OF HORMONAL VERSUS NON-HORMONAL TREATMENTS FOR MENOPAUSAL SYMPTOMS
Main Article Content
Keywords
postmenopausal syndrome, menopausal symptoms, hormonal treatment, non-hormonal treatments
Abstract
Introduction: The general symptoms of postmenopausal syndrome include; hot flashes, night sweating, mood swings, weight gain, sleeping disorders, and vaginal dryness.
Objectives: The main objective of the study is to find the comparative analysis of hormonal versus non-hormonal treatments for menopausal symptoms.
Methodology: This comparative study was conducted at the Department of Gynae, Ayub Medical Institution, Abbottabad from July 2023 to March 2024. Data were collected from 195 participants divided into two groups. Participants were randomly assigned to one of two groups: the hormonal treatment group (HRT group) or the non-hormonal treatment group (non-HRT group). All participants were required to have experienced menopausal symptoms for at least six months prior to enrollment. Participants with a history of breast cancer, cardiovascular disease, thromboembolic disorders, liver disease, or any contraindication to hormone therapy were excluded from the study. Informed consent was obtained from all participants prior to the initiation of the study.
Results: Data were collected from195 women with an average age of 52.7 years, equally distributed between peri-menopausal (40%) and post-menopausal (60%) stages across both treatment groups. The baseline characteristics were similar, with the HRT group having a mean Body Mass Index (BMI) of 26.5 compared to 27.0 in the non-HRT group. Both groups had comparable Menopause Rating Scale (MRS) scores at baseline, averaging 21.9 overall, and had been menopausal for an average of 4.7 years. The study results showed that the HRT group experienced a significant reduction in menopausal symptoms, with the Menopause Rating Scale (MRS) score decreasing from 22.1 ± 5.3 at baseline to 10.4 ± 4.8 after 12 months, representing a 53% reduction (p = 0.001).
Conclusion: It is concluded that hormonal treatments are more effective in reducing menopausal symptoms and improving quality of life compared to non-hormonal treatments.
References
2. Singh S, Dhasmana D, Dutta S, Gupta V. COMPARATIVE STUDY OF HORMONAL AND NON HORMONAL TREATMENTS FOR THE MANAGEMENT OF MENOPAUSAL SYMPTOMS. JDDT [Internet]. 13Jan.2015 [cited 2Sep.2024];5(1):82-7. Available from: https://jddtonline.info/index.php/jddt/article/view/1055
3. Palacios S, Stevenson JC, Schaudig K, Lukasiewicz M, Graziottin A. Hormone therapy for first-line management of menopausal symptoms: practical recommendations. Women’s Heal. 2019;15:1–8. doi: 10.1177/1745506519864009
4. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: implications for Timing of Early Prevention: a Scientific Statement from the American Heart Association. Circulation. 2020;142(25)
–E532. doi: 10.1161/CIR.0000000000000912
5. Faubion SS, Crandall CJ, Davis L, et al. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi: 10.1097/GME.0000000000002028
6. Marlatt KL, Redman LM, Beyl RA, Smith SR, Champagne CM, Yi FLJ. Racial differences in body composition and cardiometabolic risk during the menopause transition: a prospective, observational cohort study. Am J Obs Gynecol. 2020;222(4):365.e1–365.e18. doi: 10.1016/j.ajog.2019.09.051
7. Hachul H, Castro LS, Bezerra AG, et al. Hot flashes, insomnia, and the reproductive stages: a cross-sectional observation of women from the EPISONO study. J Clin Sleep Med. 2021;17(11):2257–2267. doi: 10.5664/jcsm.9432
8. Zhang GQ, Chen JL, Luo Y, et al. Menopausal hormone therapy and women’s health: an umbrella review. PLoS Med. 2021;18(8):1–27. doi: 10.1371/journal.pmed.1003731
9. Santoro N, Waldbaum A, Lederman S, et al. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020;27(12):1350–1356. doi: 10.1097/GME.0000000000001621
10. Lederman S, Shapiro M, Stute P, Lee M, Wang X, Neal-Perry G. Phase 3 Study of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Associated with Menopause [A132]. Obstet Gynecol. 2022;139:39S.
11. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091–1102. doi: 10.1016/s0140-6736(23)00085-5
12. Manson JAE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA. 2017;318(10):927–938. doi: 10.1001/jama.2017.11217
13. El Khoudary S, Thurston R. Cardiovascular implications of the menopause transition: endogenous sex hormones and vasomotor symptoms. ObsGynecol Clin North Am. 2018;45(4):641–661.
14. Subramanya V, Ambale-Venkatesh B, Ohyama Y, et al. Relation of Sex Hormone Levels with Prevalent and 10-Year Change in Aortic Distensibility Assessed by MRI: the Multi-Ethnic Study of Atherosclerosis. Am J Hypertens. 2018;31(7):774–783. doi: 10.1093/ajh/hpy024
15. Pinkerton JAV, Aguirre FS, Blake J, et al. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017;24(7):728–753. doi: 10.1097/GME.0000000000000921
16. Secoșan C, Balint O, Pirtea L, Grigoraș D, Bălulescu L, Ilina R. Surgically induced menopause—A practical review of literature. Med. 2019;55(8):1–10. doi: 10.3390/medicina55080482
17. Chaikittisilpa, S., Orprayoon, N., Vallibhakara, O., Vallibhakara, S. A., Tanmahasamut, P., Somboonporn, W., Rattanachaiyanont, M., Techatraisak, K., &Jaisamrarn, U. (2024). Summary of the 2023 Thai Menopause Society Clinical Practice Guideline on Menopausal Hormone Therapy. Journal of menopausal medicine, 30(1), 24–36. https://doi.org/10.6118/jmm.24006
18. Cervenka I, Al Rahmoun M, Mahamat-Saleh Y, Savoye I, Boutron-Ruault MC, Fournier A, et al. Postmenopausal hormone use and cutaneous melanoma risk: a French prospective cohort study. Int J Cancer. 2019;145:1754–1767.
19. Botteri E, Støer NC, Sakshaug S, Graff-Iversen S, Vangen S, Hofvind S, et al. Menopausal hormone therapy and risk of melanoma: do estrogens and progestins have a different role? Int J Cancer. 2017;141:1763–1770
20. Slopien R, Wender-Ozegowska E, Rogowicz-Frontczak A, Meczekalski B, Zozulinska-Ziolkiewicz D, Jaremek JD, et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6–10
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Shandana Mustafa Jadoon
Assistant Professor Department of Gynae, Ayub Teaching Hospital, Abbottabad Pakistan
Bushra Khan
Consultant Gynecologist, Oncologist, Department of Gynae, Ayub Medical Institution, Abbottabad Pakistan
Farkhanda Amir
Trainee Medical Officer Department of Gynae, Ayub Teaching Hospital, Abbottabad Pakistan
Sadia Irshad
Trainee Medical Officer Department of Gynae, Ayub Teaching Hospital, Abbottabad Pakistan
Maria Bibi
Trainee Medical Officer Department of Gynae, Ayub Teaching Hospital, Abbottabad Pakistan
Easha Jadoon
Trainee Medical Officer Department of Gynae, Ayub Teaching Hospital, Abbottabad Pakistan